Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Neumora Therapeutics, Inc. Common Stock NMRA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.25
+251.9%

Neumora Therapeutics, Inc. Common Stock (NMRA) is a Biotechnology company in the Healthcare sector, currently trading at $2.06. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is NMRA = $7 (+251.9% upside).

Valuation: NMRA trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.18.

Net income is $237M (loss), growing at -26.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $477,000 against $104M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.87 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $191M.

Analyst outlook: 6 / 9 analysts rate NMRA as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$7.25
▲ 251.94% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Neumora Therapeutics, Inc. Common Stock, the average price target is $7.25, with a high forecast of $8.00, and a low forecast of $6.00.
Highest Price Target
$8.00
Average Price Target
$7.25
Lowest Price Target
$6.00

NMRA SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NMRA

✓
VALUE Pass
100/100
NMRA trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25). Forward PEG 0.18 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $7, implying +239.8% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
NMRA: +0%/yr revenue is, -26.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet NMRA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NMRA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 6 / 9 analysts rate NMRA as buy (67%). Analyst consensus target is $7 (+239.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.611-3.65
Volume1.1M
Avg Volume (30D)1.27M
Market Cap$375M
Beta (1Y)3.12
Share Statistics
EPS (TTM)-1.45
Shares Outstanding$163.39M
IPO Date2023-09-15
Employees110
CEODaljit Singh Aurora
Financial Highlights & Ratios
Gross Profit$-5M
EBITDA$-241.16M
Net Income$-236.93M
Operating Income$-241.16M
Total Cash$182.53M
Total Debt$477K
Net Debt$-182.05M
Total Assets$191.05M
Price / Earnings (P/E)-1.4
Analyst Forecast
1Y Price Target$7.50
Target High$8.00
Target Low$6.00
Upside+264.1%
Rating ConsensusBuy
Analysts Covering9
Buy 67% Hold 11% Sell 22%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS6409791000

Price Chart

Track all markets on TradingView
NMRA
Neumora Therapeutics, Inc. Common Stock ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.61 52WK RANGE 3.65

People Also View

ALMS
ALMS
Alumis Inc. Common Stock
$24.16
+5.55%
 RAPT
RAPT
RAPT Therapeutics, Inc.
$58.01
+0.00%
 OMER
OMER
Omeros Corporation
$12.25
+3.46%
 LXRX
LXRX
Lexicon Pharmaceuticals, Inc.
$1.86
+6.29%
 PRTA
PRTA
Prothena Corporation plc
$10.82
+1.98%
 ADCT
ADCT
ADC Therapeutics S.A.
$4.37
+13.21%
 FDMT
FDMT
4D Molecular Therapeutics, Inc.
$9.77
+1.14%
 FULC
FULC
Fulcrum Therapeutics, Inc.
$8.25
+4.43%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message